Navigation Links
Acute Coronary Syndrome (ACS) Drug Market
Date:7/5/2011

9.1 Pipeline Products in the ACS Treatment Industry

9.2 The Unmet Needs of the ACS Market have Encouraged R&D

9.3 Oral Anticoagulants in Development: Progress and Setbacks

9.3.1 Apixaban, Bristol-Myers Squibb/Pfizer

9.3.1.1 Filed for VTE, but Setback for Development in ACS Patients

9.3.2 Xarelto (Rivaroxaban), Bayer HealthCare Pharma/Johnson & Johnson Pharmaceutical Research & Development

9.3.3 Pradaxa (Dabigatran), Boehringer Ingelheim

9.3.4 TAK-442 (Letaxaban), Takeda Pharmaceuticals

9.4 Novel Parenteral Anticoagulants: Offering Advantages over the Current Standard of Care?

9.4.1 Otamixaban, Sanofi-Aventis

9.4.1.1 Rapid Onset of Action and Short Half-Life

9.4.2 REG1, Regado Biosciences

9.4.2.1 First Aptamer Drug for the Treatment of ACS

9.4.2.2 In Phase II Clinical Trials for ACS

9.5 Direct ADP Receptor Antagonists: Providing Rapid Onset and Offset of Action

9.5.1 Brilinta (Ticagrelor), AstraZeneca

9.5.1.1 Rejected for Reimbursement in France: Another Setback after Delay of Approval in the US

9.5.1.2 Factors Favouring Brilinta: A New Class of Drug

9.5.2 Elinogrel (PRT128), Novartis/Portola Pharmaceuticals

9.5.3 Cangrelor, The Medicines Company

9.6 Thrombin Receptor Antagonists: Novel Antiplatelet Drugs

9.6.1 Vorapaxar, Merck & Co.

9.6.1.1 Setback for a Promising Candidate

9.6.2 E555 (Atopaxar), Eisai

9.7 Other Drugs in Development for ACS

10. Qualitative Analysis of the Industry and Market

10.1 Strengths and Weaknesses of the Sector

10.1.1 Increasing Prevalence of Disease Drives the Market

10.1.2 High Mortality Rates: Leading Cause of Death in Developed Countries

10.1.3 Available Treatments Have Been Successful in Reducing Mortality Rate

10.1.4 High Economic Cost of Disease

10.2 Opportunities and Threats

10.2.1 Deve
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
2. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
3. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
4. NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics With Acute Myocardial Infarction
5. Nile Therapeutics Receives Fast Track Designation for Cenderitide for Post-Acute Indication
6. International Medical Corps Team in Hardest-Hit Coastal Communities Finds Severe Shortages of Food, Water, Medicines; Acute Need for Mental Health Support
7. Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
8. Allscripts Demonstrates Native Integration of Acute and Ambulatory Electronic Health Records at HIMSS
9. University Hospitals Selects Allscripts Electronic Health Record for 1,400 Physicians and Expands Sunrise™ Enterprise Acute Care EHR in Eight Hospitals
10. FDA Issues Complete Response Letter Regarding Acetadote® Supplemental New Drug Application for Acute Liver Failure
11. By 2019, the Acute Gout Drug Market Will Triple in Size While the Chronic Gout Drug Market Will Reach $1.83 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Eisai Corporation of North America today announced that the ... review the company,s supplemental new drug application (sNDA) for ... injection) to treat patients with myelodysplastic syndromes (MDS). ... diseases that limit the production of functional blood cells. ...
... Amgen (Nasdaq: AMGN ) today announced that ... Zometa(R) (zoledronic acid) in the treatment of bone metastases ... primary and secondary endpoints and demonstrated superior efficacy compared ... the time to the first on-study Skeletal Related Events ...
Cached Medicine Technology:FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS) 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/23/2014)... bottom of Alzheimer,s disease has been a rapidly ... In the latest crook in the research road, ... interaction between proteins associated with the disease. The ... Chemical Neuroscience , could have important implications for ... Nieznanski and colleagues explain that for years, research ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... blood vessel walls can vary among individuals depending on factors ... research at UC Davis. The new research reinforces the ... linings that can lead to heart disease and strokes. ... cholesterol," known to increase risk of inflammation of the endothelium, ...
... Salamon HealthDay Reporter , THURSDAY, Feb. 17 (HealthDay ... weeks early has no discernible impact on babies, a new ... than their full-term peers and those delays may affect their ... term and 1,200 late preterm infants -- those born between ...
... 2011) Two studies published in the current issue ... islet cell transplantation for treating diabetes. Researchers in Milan, ... in diabetic therapy and islet cell regeneration and Canadian ... in vitro. Both studies are in the ...
... Feb. 17 (HealthDay News) -- The area of the brain ... that suggests the brain is a "task machine" instead of ... brain scans, the researchers measured neural activity in eight blind ... blind since birth, showed activity in the exact same part ...
... cell phone use does not appear to increase the ... a study by University of Manchester scientists suggests. ... Office of National Statistics to look at trends in ... 1998 and 2007. The study, published in the ...
... urban public housing spend more time playing outdoors than ... Columbia University and Princeton University. Contrary to ... living in poorer circumstances would be playing outside less, ... played outside 13 percent more per day, on average, ...
Cached Medicine News:Health News:Study reinforces link between obesity, high-fat meals and heart disease 2Health News:Delivery Even a Bit Early May Mean Developmental Delays 2Health News:Delivery Even a Bit Early May Mean Developmental Delays 3Health News:Researchers work at the frontiers of islet cell transplantation 2Health News:Researchers work at the frontiers of islet cell transplantation 3Health News:Cell-phone use not related to increased brain cancer risk 2Health News:Children in public housing play outdoors more 2
... a sterile nonpyrogenic, transparent viscoelastic solution of ... mg/mL of high molecular weight (greater than ... physiological saline. In the limit of zero ... (105 Pa s) at 25C, and the ...
Orbital Retractor, schepens Retractors, overall length:154mm....
... places fast and accurate visual ... Utilising standard computer hardware and ... with new testing and display ... integrated into a modern ophthalmic ...
... With a test capability extending to 80, ... a patient's visual field, allowing peripheral defects ... field to be explored. Practice Management Integration ... practice. With the Medmont Studio package the ...
Medicine Products: